METUPUK welcomes the Scottish Medicines Consortium (SMC) acceptance of Trodelvy® (sacituzumab govitecan) for use within NHSScotland.
Trodelvy is an innovative drug which has been accepted for the treatment metastatic triple-negative breast cancer (mTNBC) within NHSScotland. Metastatic triple-negative breast cancer is a challenging disease to treat, and an even more devastating disease to live with.
METUPUK welcome the National Institute of Clinical Excellence (NICE) decision to accept Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies for routine commissioning use in NHS in England and Wales.
I was diagnosed with Grade 3 primary breast cancer in my left breast in January 2016 and am now cancer free. That sounds great to me. I’m one of the
It was shocking to hear the Prime Minister dismiss the importance of cancer outcomes in such an offhand way in a TV interview this week. But at the same time, it was sadly not surprising to many of us at Met-Up UK.
Under NICE rules, I would not be eligible to receive the medication that I am currently taking for my metastatic breast cancer on the NHS. I have been on my current drug regime since 2017, I am feeling really well, my disease is stable, and my scans are clear.
I began taking Palbociclib over 3 years ago, badgering my Oncologist and accessing it through a free trial set up by Pfizer. The trial was designed to sway NICE into approving the drug for NHS use, despite it’s high price.
I have been living with secondary breast cancer for 7 years, and am very aware that I’m one of the very lucky ones as the median life expectancy is 2-3 years. The general public perception of breast cancer is that it’s ‘sorted’ – eg if you get it you will be fine. But few people realise that when it metastases (spreads) to the organs as mine has, it cannot be cured. It is the biggest killer of women under 50 with over 11,000 women dying of it every year in the UK.
On March 22nd In Wales, the 20 page cancer delivery plan (CDP) had been replaced by a vague 3 quality statement. (QS)
The WHO recommends every nation should have a CDP and just like that Wales became the only nation in the UK without one.
We really need to raise awareness around what people with secondary cancer require, encouraging the debate to be placed upon the policy table. You can really help us by writing
Our April email. 17.4.20 Dear Jo, Jo, Leslie, Beth and all at METUP UK, I hope you and your families are okay at this difficult time. Thank you for being in
“Patient advocacy is an area of specialization in health care concerned with advocacy for patients, survivors, and caregivers. The patient advocate may be an individual or an organization, often, though
